NEW YORK – August 26, 2026 – The Cardiovascular Research Foundation ® (CRF ® ) announced the late-breaking clinical trials and science selected for presentation at TCT ® 2026, the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. This year’s conference will take place October 31–November 3 at the San Diego Convention Center bringing together leading investigators, clinicians, and innovators from around the world.
For more than three decades, TCT has been at the forefront of advancing cardiovascular medicine, serving as the global stage for groundbreaking research and innovation. The meeting is recognized for unveiling pivotal data that informs clinical decision-making, drives practice-changing innovation, and ultimately improves outcomes for patients with heart and vascular disease.
Among the most highly anticipated presentations at TCT are the Late-Breaking Clinical Trials and Science sessions, which provide first access to landmark research findings, emerging therapies, novel devices, and cutting-edge treatment strategies. This year, 28 studies will be featured, highlighting advances in minimally invasive interventions, pharmaceutical therapies, and breakthrough technologies designed to prevent, manage, and treat cardiovascular disease.
These high-impact findings will be featured in the main program and spotlighted during dedicated press briefings on Sunday, November 1, Monday, November 2, and Tuesday, November 3.
Sunday, November 1
Coronary CT Angiography-Guided vs. IVUS-Guided PCI: The Randomized P4 Trial
Carlos Collet
Sirolimus Coated Balloons vs. Drug-Eluting Stents in Native Coronary Vessels: The TRANSFORM II Randomized Trial
Bernardo Cortese
A Randomized Trial of Higher vs. Lower Dose Heparin for PCI: The HD-PCI Trial
Sanjit Jolly
Coronary Sinus Reducer for Refractory Angina in ANOCA: A Randomized Double-Blind Sham-Controlled Trial (REMEDY-PILOT)
Kevin Cheng
Characteristics and Clinical Outcomes of Tricuspid Regurgitation in the Community: Insights from a Real-World Cohort of 180,977 Men and Women
Rebecca Hahn
Transcatheter Tricuspid Valve Replacement with the LuX-Valve Plus System vs. Medical Therapy for Severe TR: The Randomized TRAVEL III Trial
Junbo Ge
Transcatheter Tricuspid Valve Intervention in Heart Failure: Key Subgroup Results from the TRIC-I-HF-DZHK24 Trial
Jörg Hausleiter
One-Year Outcomes with the Amulet 360 Device for Left Atrial Appendage Closure: The VERITAS Amulet 360 Study
Dhanunjaya Lakkireddy
Left Atrial Appendage Closure vs. Contemporary Medical Therapy for Stroke Prevention in AF (LANTERN): An IPD Meta-Analysis of Randomized Trials
Rohin Reddy
Monday, November 2
TAVR or Clinical Surveillance for Moderate Aortic Stenosis: Primary Results of the PROGRESS Randomized Trial
Philippe Genereux
Transcatheter Tricuspid Valve Repair with the PASCAL System vs. Medical Therapy for Severe, Symptomatic Tricuspid Regurgitation: Clinical and Health Status Outcomes from the CLASP II TR Randomized Trial
Charles Davidson
Suzanne Arnold
Global Burden and Outcomes of Degenerative Mitral Valve Disease: A 30-Year Analysis of the Global Burden of Disease Study
Juan Granada
Antithrombotic Monotherapy After Left Atrial Appendage Occlusion: Primary Results of the SIMPLAAFY Randomized Trial
Saibal Kar
One-Year Outcomes of the PeriSorb Bioresorbable Vascular Scaffold vs. Drug-Coated Balloon for Superficial Femoral Artery Disease: A Multicenter Randomized Trial
Yuan Che
Three-Year Outcomes of Sirolimus vs. Paclitaxel-Coated Balloons for Femoropopliteal Artery Disease: The Randomized SIRONA Trial
Ulf Teichgräber
Impact of Non-Culprit Lesion Severity on the Utility of Functional Coronary Angiography in Patients with STEMI and Multivessel Disease: The AIR STEMI Randomized Trial
Simone Biscaglia
Angiography-Derived FFR Versus vs. Wire-Based FFR to Guide Coronary Revascularization: The LIPSIA-STRATEGY Trial
Nicolas Majunke
Intracoronary Delivery of Nicorandil for Prevention of No-Reflow Patients Undergoing Primary PCI for STEMI: A Multicenter Randomized Trial
Takashi Muramatsu
Tuesday, November 3
Angiography-Derived FFR vs. Usual Care for Lesion Selection and Optimization in All-Comers PCI: Final Results of the PIONEER IV Randomized Trial
Patrick Serruys
Platelet Function Testing to Guide P2Y12 Inhibitor De-Escalation After ACS: The EPIC17-VERONICA Randomized Trial
Iñigo Lozano
Safety and Effectiveness of Radiofrequency Renal Denervation in the United States: Primary Results of the SPYRAL AFFIRM Post-Approval Study
David Kandzari
Single vs. Double ProGlide Devices for Access Site Closure After Transfemoral TAVR: The SINGLE-CLOSURE Trial
Jian’an Wang
The ProtEmbo® Cerebral Protection System During TAVR: Final Results of the Randomized PROTEMBO IDE Trial
Susheel Kodali
Transcatheter vs. Surgical AVR for Symptomatic, Severe Aortic Regurgitation: One-Year Outcomes from a Multicenter Randomized Trial
Xiaoping Peng
Transcatheter Aortic Valve Replacement with the JenaValve Trilogy System for Aortic Regurgitation in Patients with a Left Ventricular Assist Device: The JENA-VAD Study
Ravi Ramana
Economic Outcomes and Cost-Effectiveness of TAVR for Asymptomatic Severe Aortic Stenosis: Results from the EARLY TAVR Trial
Neel Butala
Routine Post-Dilation vs. Conventional Deployment for Balloon-Expandable TAVR: The Randomized DUOTAP Trial
Maximilian Autherith
Percutaneous Transcatheter Mitral Valve Replacement in Patients with Symptomatic Mitral Regurgitation: 2-Year Outcomes from the ENCIRCLE Trial
John G. Webb
Media are invited to attend TCT® and can apply for media credentials at: https://www.tctconference.com/press-registration .
Receive updates on X at https://x.com/TCTConference and https://x.com/crfheart .
About CRF ® and TCT ®
The Cardiovascular Research Foundation ® (CRF ® ) is a global leader in interventional cardiovascular medicine, driving innovation, spearheading groundbreaking research, and transforming education in the field. Through its relentless pursuit of excellence, CRF not only accelerates medical breakthroughs but also equips healthcare professionals with the tools and knowledge necessary to enhance survival rates and elevate the quality of life for millions worldwide. CRF’s centers of excellence include the CRF Skirball Center for Innovation, CRF Clinical Trials Center, CRF Center for Education, CRF Digital, TCTMD ® , and Structural Heart: The Journal of the Heart Team .
Transcatheter Cardiovascular Therapeutics ® (TCT®) is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. Anchored in a legacy spanning over three decades, TCT is a world-class educational experience featuring disruptive innovation, scientific breakthroughs, expert-led tutorials, hands-on training, and ample opportunities for networking and collaboration.
For more information, visit www.crf.org and www.tctconference.com .
###